跳至主要内容
临床试验/NCT02766439
NCT02766439已完成不适用

the First People's Hospital of Chenzhou

Yang Beibei0 个研究点目标入组 6 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
6
主要终点
Disease Activity Score in 28 Joints (DAS28)

研究概览

简要总结

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

详细描述

between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1

排除标准

  • those who had participated in other studies

研究组 & 干预措施

Rhupus syndrome, SLE without RA

Rhupus syndrome, SLE without RA

干预措施: etanercept (Drug)

结局指标

主要结局

Disease Activity Score in 28 Joints (DAS28)

时间窗: 24 week

次要结局

未报告次要终点

研究者

发起方
Yang Beibei
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Yang Beibei

the First People's Hospital of Chenzhou

First People's Hospital of Chenzhou

相似试验